ライフサイエンスコーパス: Rous

1 Rous sarcoma virus (RSV) and murine leukemia virus (MLV)

2 Rous sarcoma virus (RSV) and murine leukemia virus (MLV)

3 Rous sarcoma virus (RSV) budding requires an interaction

4 Rous sarcoma virus (RSV) Gag nuclear cycling is a unique

5 Rous sarcoma virus (RSV) promoter-driven expression of t

6 Rous sarcoma virus (RSV) requires large amounts of unspl

7 Rous sarcoma virus (RSV), a simple retrovirus, needs to

8 Rous sarcoma virus (RSV)-tk bearing the HSV1-tk gene wer

9 Rous sarcoma virus pre-mRNA contains an element known as

10 Rous sarcoma virus RNA contains a negative regulator of

11 Rous spent his entire research career at The Rockefeller

12 human immunodeficiency virus type 1 (HIV-1), Rous sarcoma virus (RSV), and Mason-Pfizer monkey virus

13 novirus containing the HERG gene driven by a Rous sarcoma virus (RSV) promoter.

14 as an inducible HIV-1 genome controlled by a Rous sarcoma virus promoter with lac operator sequences.

15 We have constructed and characterized a Rous sarcoma virus-based retroviral vector with the host

16 of the NC domain in assembly of VLPs from a Rous sarcoma virus (RSV) Gag protein and have characteri

17 In this report, a Rous sarcoma virus (RSV) mutant having two acidic-to-bas

18 The cellular receptor for subgroup A Rous sarcoma virus (RSV) contains a single LDL-A module

19 Tva is the receptor for subgroup A Rous sarcoma virus, and it contains a single LDL-A modul

20 It was shown previously that a Rous sarcoma virus Gag protein missing only the protease

21 endogenously expressing SDF-1/CXCL12 under a Rous sarcoma virus promoter were produced.

22 ol vector containing a constitutively active Rous sarcoma virus (RSV) viral promoter driving the luci

23 riptional control of a constitutively active Rous sarcoma virus promoter was regulated identically to

24 eplication-defective adenoviral vectors [Adv.Rous sarcoma virus (RSV)-nf] representing three families

25 a mouse monoclonal antibody directed against Rous sarcoma virus (RSV) subgroup A Env that will be use

26 red that the oncogenic avian alpharetrovirus Rous sarcoma virus (RSV) Gag protein undergoes transient

27 ssed this question using the alpharetrovirus Rous sarcoma virus (RSV) as a model system.

28 we have examined whether the alpharetrovirus Rous sarcoma virus (RSV) is susceptible to inhibition by

29 , a Gammaretrovirus, and the Alpharetrovirus Rous sarcoma virus (RSV), were susceptible to inhibition

30 -membrane interaction of the alpharetrovirus Rous sarcoma virus (RSV).

31 this model, CA proteins from both HIV-1 and Rous sarcoma virus (RSV) form similar hexagonal lattices

32 In HIV-1 and Rous sarcoma virus, this region forms a rod-like structu

33 an immunodeficiency virus type 1 (HIV-1) and Rous sarcoma virus (RSV) capsid proteins form a beta-hai

34 ts within the avian leukosis virus (ALV) and Rous sarcoma virus (RSV) LTR enhancers in a pattern iden

35 V), feline immunodeficiency virus (FIV), and Rous sarcoma virus (RSV) to critically address the role

36 rowth Factor Receptor Substrate 2 (Frs2) and Rous sarcoma oncogene (Src) Homology Phosphatase 2 (Shp2

37 ogous positions in visna virus integrase and Rous sarcoma virus integrase changed the target site pre

38 tures found in osteoclasts, macrophages, and Rous sarcoma virus (RSV)-transformed fibroblasts.

39 unodeficiency virus type 1, visna virus, and Rous sarcoma virus exhibited different target site prefe

40 o- deficiency virus type 1, visna virus, and Rous sarcoma virus exhibited distinct preferences for wa

41 1) and 2, simian immunodeficiency virus, and Rous sarcoma virus.

42 t, the L domains of oncoretroviruses such as Rous sarcoma virus (RSV) have a more N-terminal location

43 ture of the CA domains in immature assembled Rous sarcoma virus Gag particles.

44 ent of Gag in in vivo and in vitro assembled Rous sarcoma virus (RSV) particles and to compare these

45 ng a well-established retroviral model-avian Rous sarcoma virus (RSV)-we analyzed changes in an RSV v

46 Production of avian Rous-associated virus type 1 was also impaired by PARP-1

47 e experiments reported here, using the avian Rous sarcoma virus as a model system, further define the

48 ct of the retroviral M domain from the avian Rous sarcoma virus is defined and its solution structure

49 In particular, although both Rous sarcoma virus (RSV) and AMV could replicate in cult

50 tained human factor IX (hFIX) cDNA driven by Rous sarcoma virus long terminal repeat in the E1 region

51 r carrying the cDNA for C/EBPalpha driven by Rous sarcoma virus promoter elements (AdCEBPalpha) or a

52 ansforming viral oncogene product encoded by Rous sarcoma virus (RSV).

53 chicken embryo fibroblasts (CEF) infected by Rous sarcoma virus against a confluent background of uni

54 Cell transformation by Rous sarcoma virus results in a dramatic change of adhes

55 In chick embryo fibroblasts transformed by Rous sarcoma virus (RSV) the tyrosine phosphorylation of

56 er ALV was found in stocks of RSV and called Rous-associated virus (RAV).

57 essential steps in understanding the chicken Rous sarcoma virus (RSV) genome association with a nonpe

58 ld be initiated by electroporation of cloned Rous sarcoma virus (RSV) proviral DNA into the developin

59 cytes, with proteins that negatively control Rous sarcoma oncogene cellular homolog (Src) activity.

60 We have identified an assembly-defective Rous sarcoma virus (RSV) Gag mutant that retains signifi

61 plasmid acceptor, purified bacterium-derived Rous sarcoma virus integrase (IN), and a host cell DNA-b

62 f a weak src 3'ss is necessary for efficient Rous sarcoma virus replication.

63 s containing TATA and/or initiator elements, Rous sarcoma virus and thymidine kinase promoters in BeW

64 Although the integrity of the entire Rous sarcoma virus leader sequence is important for retr

65 rescence correlation spectroscopy-to examine Rous sarcoma virus Gag-Gag and -membrane interactions in

66 For Rous sarcoma virus (RSV), Gag proteins are synthesized i

67 For Rous sarcoma virus (RSV), the size determinant maps to t

68 iruses containing the cellular receptors for Rous sarcoma virus (Tva) or ecotropic murine leukemia vi

69 Since codon composition values for Rous sarcoma virus distinguished a "foreign" gene from t

70 ive regulator of splicing (NRS) element from Rous sarcoma virus.

71 odel retroviral envelope protein (EnvA) from Rous sarcoma virus (RSV).

72 structure of the three-domain integrase from Rous sarcoma virus in complex with viral and target DNAs

73 he negative regulator of splicing (NRS) from Rous sarcoma virus suppresses viral RNA splicing and is

74 totally unrelated late domain sequences from Rous sarcoma virus (contained in its p2b sequence) or eq

75 natural or mutated 5' leader sequences from Rous sarcoma virus were expressed in avian cells in the

76 e-bound nonreceptor tyrosine kinase Src from Rous sarcoma virus, these interactions are mediated by a

77 variety of specimens assembled in vitro from Rous sarcoma virus (RSV) CA.

78 only 2.6-fold less efficiently than genomic Rous sarcoma virus RNA.

79 downstream from the 3'ss of the heterologous Rous sarcoma virus src gene.

80 triphosphate [PI(3,4,5)P(3)] levels impaired Rous sarcoma virus (RSV) Gag PM localization.

81 In Rous sarcoma virus, previous studies have identified imp

82 In Rous sarcoma virus, splicing control is achieved in part

83 the robustly induced enzymatic activities in Rous sarcoma virus (RSV)-transformed chicken cells.

84 erve as mRNA for the envelope protein and in Rous sarcoma virus as src mRNA.

85 ng (NRS) is a long cis-acting RNA element in Rous sarcoma virus that contributes to unspliced RNA acc

86 is tyrosine-phosphorylated when expressed in Rous sarcoma virus-infected chicken embryo fibroblasts (

87 peat (DR) sequences flanking the src gene in Rous sarcoma virus are essential posttranscriptional con

88 osed based on the existence of MA mutants in Rous sarcoma virus (RSV), murine leukemia virus, human i

89 stablishment of the transformed phenotype in Rous sarcoma virus (RSV)-infected cells.

90 initially identified as a phosphoprotein in Rous sarcoma virus-transformed cells.

91 gate Gag protein structure and processing in Rous sarcoma virus, the prototype of the avian sarcoma a

92 About one-third of the MA protein in Rous sarcoma virus (RSV) is phosphorylated.

93 by his discovery of reverse transcriptase in Rous sarcoma virus virions.

94 In some orthoretroviruses, including Rous Sarcoma Virus (RSV), CA carries a short and hydroph

95 virus-based vector LNCX, contain an internal Rous sarcoma virus (RSV) or cytomegalovirus (CMV) promot

96 and -uncoupled pathways; the latter involved Rous sacracoma virus homolog genes-encoded tyrosine kina

97 tudy in vitro-assembled, immature virus-like Rous sarcoma virus (RSV) Gag particles and have determin

98 in vitro flotation assay to directly measure Rous sarcoma virus (RSV) MA-membrane interaction in the

99 HIV-1, Moloney murine leukemia virus (MLV), Rous sarcoma virus (RSV), and human T-cell lymphotropic

100 roviruses that undergo type C morphogenesis, Rous sarcoma virus and human immunodeficiency virus, whi

101 e 3' splice site in the BPV-1 late pre-mRNA, Rous sarcoma virus src pre-mRNA, human immunodeficiency

102 We have previously described a mutant Rous sarcoma virus (RSV) Env protein, Env-mu26, with an

103 We previously reported that a mutant Rous sarcoma virus (RSV) with an alternate polypurine tr

104 enzyme, resulting in a highly active mutant Rous sarcoma virus (RSV) protease that displays many cha

105 We have examined mutant Rous sarcoma virus envelope proteins with truncations or

106 erminal 100 residues of the non-myristylated Rous sarcoma virus (RSV) Gag protein.

107 the utility of the system, we developed new Rous sarcoma virus (RSV)-based replication-incompetent v

108 HT29, and CaCo2) compared with a nonspecific Rous sarcoma virus-yCD virus.

109 nhanced when the serine at amino acid 124 of Rous sarcoma virus (RSV) integrase is replaced by alanin

110 sembly incompetent by testing the ability of Rous sarcoma virus (RSV) CA-SP to assemble in vitro into

111 immunodeficiency virus type 1 (HIV-1) and of Rous sarcoma virus (RSV) are morphologically distinct wh

112 t here that IP6 is also used for assembly of Rous sarcoma virus (RSV), a retrovirus from a different

113 d-state NMR (ssNMR) resonance assignments of Rous sarcoma virus (RSV) CA, assembled into hexamer tube

114 nalyses of two in-vitro-assembled capsids of Rous sarcoma virus.

115 In the case of Rous sarcoma virus (RSV), the size determinant maps to t

116 The discovery of Rous sarcoma virus (RSV) led to the identification of ce

117 The discovery of Rous sarcoma virus, which was reported by Peyton Rous in

118 The major late domain of Rous sarcoma virus (RSV) has been mapped to a PPPY motif

119 The L domain of Rous sarcoma virus (RSV) has been shown to interact with

120 A PPPPY motif within the L domain of Rous sarcoma virus (RSV) was previously characterized as

121 resembles the PPPPY motif in the L domain of Rous sarcoma virus (RSV), an avian retrovirus.

122 ences that exist in the C-terminal domain of Rous sarcoma virus capsid relative to the other capsid p

123 here that while deletion of the NC domain of Rous sarcoma virus Gag abolishes formation and budding o

124 The late assembly domain (L-domain) of Rous sarcoma virus (RSV) or human immunodeficiency virus

125 membrane binding, we fused the MA domains of Rous sarcoma virus (RSV) and HIV-1 to the chemically ind

126 icles (VLPs), we observed that expression of Rous sarcoma virus Gag failed to produce VLPs.

127 that allowed for the first-time formation of Rous sarcoma virus CA into structures resembling authent

128 ous studies revealed that truncated forms of Rous sarcoma virus integrase containing two of the three

129 med spontaneously in vitro from fragments of Rous sarcoma virus (RSV) Gag protein purified after expr

130 homologue of v-src, the transforming gene of Rous Sarcoma virus.

131 ned 70S RNA closely related to the genome of Rous-associated virus type 0, but identifiable as the ev

132 resolution of a fragment of the integrase of Rous sarcoma virus (residues 49-286) containing both the

133 that of the naturally nonmyristoylated MA of Rous sarcoma virus.

134 During assembly and morphogenesis of Rous sarcoma virus (RSV), proteolytic processing of the

135 structure of the N-terminal domain (NTD) of Rous sarcoma virus (RSV) capsid protein (CA), with an up

136 dentified in the gag-specific protein p2b of Rous sarcoma virus.

137 Expression of the Gag-Pol polyprotein of Rous sarcoma virus (RSV) requires a -1 ribosomal framesh

138 t the enzymatic and structural properties of Rous sarcoma virus (RSV) PR are exquisitely sensitive to

139 The Gag protein of Rous sarcoma virus (RSV) can direct particle assembly an

140 describes new mutations in the CA protein of Rous sarcoma virus (RSV) that were designed to test whet

141 ne transport, the multidomain Gag protein of Rous sarcoma virus (RSV) undergoes importin-mediated nuc

142 a mutant of the viral matrix (MA) protein of Rous sarcoma virus that disrupts viral RNA dimerization.

143 domain that is present in the Gag protein of Rous sarcoma virus.

144 The Gag proteins of Rous sarcoma virus (RSV) and human immunodeficiency viru

145 The Gag proteins of Rous sarcoma virus (RSV) and human immunodeficiency viru

146 ric interactions between the Gag proteins of Rous sarcoma virus (RSV).

147 The 5' untranslated region of Rous sarcoma virus (RSV) RNA is a highly ordered structu

148 inding site in the 5' untranslated region of Rous sarcoma virus (RSV) RNA play an integral role in mu

149 ing element in the 3' untranslated region of Rous sarcoma virus (RSV) RNA was found to promote Rev-in

150 the cell dramatically reduced the release of Rous sarcoma virus, an avian retrovirus.

151 to as antisense, can inhibit replication of Rous sarcoma virus through hybridization to viral RNA.

152 er of cis-acting sequences within the RNA of Rous sarcoma virus play a role in preserving a large poo

153 In vivo screening of Rous sarcoma virus mutants was performed with randomly m

154 eption was the 11-amino-acid p2b sequence of Rous sarcoma virus (RSV) Gag, which could fully restore

155 L vitiligo by using the complete sequence of Rous-associated virus-2 as a probe for EV.

156 onducted to investigate the initial steps of Rous sarcoma virus (RSV) assembly by examining the assoc

157 the Gag protein; however, recent studies of Rous sarcoma virus (RSV) and human immunodeficiency viru

158 n the SU and TM envelope protein subunits of Rous sarcoma virus and murine leukemia virus.

159 d CRM1-dependent nuclear cycling was that of Rous sarcoma virus (RSV).

160 ze budding of virus-like particles (VLPs) of Rous sarcoma virus (RSV) and HIV type 1 (HIV-1).

161 eplication-competent shuttle vector based on Rous sarcoma virus (RSV), with alternate retroviral PPTs

162 ses, including the prototypic oncoretrovirus Rous sarcoma virus, were synthesized on cytosolic riboso

163 However, in the presence of budding HIV-1 or Rous sarcoma virus (RSV) particles, some glycoproteins,

164 from human immunodeficiency virus type 1 or Rous sarcoma virus, respectively.

165 ontrol of the human cytomegalovirus (CMV) or Rous sarcoma virus (RSV) promoters.

166 HIT, and CHO cells using cytomegalovirus or Rous sarcoma virus promoters.

167 , human immunodeficiency virus type 1 p6, or Rous sarcoma virus p2b.

168 mmunodeficiency virus type 1 (HIV-1) PTAP or Rous sarcoma virus (RSV) PPPY L domain in the p9 protein

169 American Society for Investigative Pathology Rous-Whipple Award Lecture 2021.

170 Peyton Rous and others demonstrated the process of co-carcinoge

171 Peyton Rous founded this scientific field in 1911 by discoverin

172 One hundred years ago Peyton Rous recovered a virus, now known as the Rous sarcoma vi

173 In 1911, more than a century ago, Peyton Rous described a curious observation, later explained by

174 sarcoma virus, which was reported by Peyton Rous in the Journal of Experimental Medicine 100 years a

175 vector encoding a peptide inhibitor of PKA [Rous sarcoma virus (RSV)-protein kinase A inhibitor (PKI

176 binding chicken Y-box protein that promotes Rous sarcoma virus long terminal repeat (RSV LTR)-driven

177 ssociation of HIV-1 Gag, as well as purified Rous sarcoma virus (RSV) MA and Gag, depends strongly on

178 We have purified Rous sarcoma virus (RSV) Gag protein and in parallel sev

179 Using purified Rous sarcoma virus Gag and Gag truncations, we studied t

180 is virus integrase and bacterial recombinant Rous sarcoma virus (Prague A strain) integrase (approxim

181 Site-directed mutagenesis of recombinant Rous sarcoma virus (RSV) integrase (IN) allowed us to ga

182 of four promoters (dihydrofolate reductase, Rous sarcoma virus, long terminal repeat, or cytomegalov

183 nducible, constitutively expressed reporter, Rous sarcoma virus-luciferase (RSV-LUC); nor does it blo

184 Uniquely, the simple retrovirus Rous sarcoma virus (RSV) has a Gag structural protein th

185 In prior studies of the retrovirus Rous sarcoma virus (RSV), we observed that the Gag prote

186 articles of the prototypic avian retrovirus, Rous sarcoma virus (RSV), by using scanning transmission

187 We asked whether a single Rous sarcoma virus (RSV) RNA can be translated and subse

188 produce milligram quantities of the soluble Rous sarcoma virus (RSV) synaptic complex that is kineti

189 We produced kinetically stabilized Rous sarcoma virus (RSV) intasomes with human immunodefi

190 A direct comparison demonstrates that Rous sarcoma virus is capable of infecting aphidicolin-a

191 We find that Rous sarcoma virus virions, like the human immunodeficie

192 The Rous sarcoma virus (RSV) Gag polyprotein undergoes trans

193 The Rous sarcoma virus (RSV) Gag precursor polyprotein is th

194 The Rous sarcoma virus (RSV) is an exception, in that its ge

195 The Rous sarcoma virus (RSV) long terminal repeat (LTR) cont

196 The Rous sarcoma virus (RSV) long terminal repeat (LTR) cont

197 The Rous sarcoma virus (RSV) negative regulator of splicing

198 The Rous sarcoma virus (RSV) polyadenylation site (PAS) is v

199 The Rous sarcoma virus (RSV) transmembrane (TM) glycoprotein

200 The Rous sarcoma virus gag gene contains a cis-acting negati

201 The Rous sarcoma virus Gag protein undergoes transient nucle

202 The Rous sarcoma virus protease displays a high degree of sp

203 1 is shown to transcriptionally activate the Rous sarcoma virus-long terminal repeat promoter, which

204 ton Rous recovered a virus, now known as the Rous sarcoma virus (RSV), from a chicken sarcoma, which

205 Other substrates such as the Rous sarcoma virus protein NC are phosphorylated by gamm

206 olecular disulfide bond during assembly, the Rous sarcoma virus capsid protein does not.

207 he cDNA for human iNOS was cloned behind the Rous sarcoma virus (RSV) promoter to create adenovirus (

208 on of baby hamster kidney fibroblasts by the Rous sarcoma virus causes a significant increase in the

209 antibiotic-resistance gene was driven by the Rous sarcoma virus long terminal repeat or the herpes si

210 ngeable late assembly domains carried by the Rous sarcoma virus p2b protein and human immunodeficienc

211 which sig-mEndo expression was driven by the Rous sarcoma virus promoter had moderately high serum le

212 porter beta-galactosidase gene driven by the Rous Sarcoma Virus promoter.

213 ch controls fibroblast transformation by the Rous sarcoma virus.

214 eat honor that my work was recognized by the Rous-Whipple Award this past year, giving me the opportu

215 cloned into a pMAMneo vector containing the Rous sarcoma virus promoter and the neomycin resistance

216 135-nucleotide (nt) direct repeats flank the Rous sarcoma virus (RSV) oncogene src and are composed o

217 0 amino acid residue capsid protein from the Rous sarcoma virus has been determined by NMR methods.

218 2(1) collagen promoters and 10-fold from the Rous sarcoma virus long terminal repeat.

219 We previously identified the Rous sarcoma virus (RSV) stability element (RSE), an RNA

220 In the Rous sarcoma virus (RSV) Gag protein, the 25 amino-acid

221 In the Rous sarcoma virus (RSV) Gag protein, the M domain is co

222 the site phosphorylated by gamma-PAK in the Rous sarcoma virus nucleocapsid protein NC in vivo and i

223 ng stimulatory element was discovered in the Rous sarcoma virus.

224 Instead, the Rous sarcoma virus capsid protein contains a single cyst

225 During virion maturation, the Rous sarcoma virus (RSV) capsid protein is cleaved from

226 The first few residues of the Rous sarcoma virus (RSV) CA protein comprise a structura

227 of charged residues in the FL region of the Rous sarcoma virus (RSV) CA to particle assembly.

228 The p2 region of the Rous sarcoma virus (RSV) Gag polyprotein contains an ass

229 Nucleocytoplasmic shuttling of the Rous sarcoma virus (RSV) Gag polyprotein is an integral

230 Proteolytic processing of the Rous sarcoma virus (RSV) Gag precursor was altered in vi

231 The first 86 residues of the Rous sarcoma virus (RSV) Gag protein form a membrane-bin

232 ously reported that nuclear transport of the Rous sarcoma virus (RSV) Gag protein is intrinsic to the

233 ped three very small, modular regions of the Rous sarcoma virus (RSV) Gag protein that are necessary

234 een these two hypotheses, we made use of the Rous sarcoma virus (RSV) Gag protein, the PR of RSV IS i

235 elatively short, 82 nucleotide region of the Rous sarcoma virus (RSV) genome, called muPsi, was shown

236 taining the ts gene under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) and

237 eracts with the Schmidt-Ruppin strain of the Rous sarcoma virus (RSV) long terminal repeat (LTR) betw

238 CC-3' present on the noncoding strand of the Rous sarcoma virus (RSV) long terminal repeat (LTR) in a

239 eceptor (ecoR) cDNA under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) prom

240 rted repeat (IR) within the U5 region of the Rous sarcoma virus (RSV) mRNA forms a structure composed

241 the single-particle cryo-EM structure of the Rous sarcoma virus (RSV) strand transfer complex (STC) i

242 y reactions with purified CA proteins of the Rous sarcoma virus (RSV) were used to define factors tha

243 tween the PBS and the CA dinucleotide of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z to matc

244 the endogenous polypurine tract (PPT) of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z was rep

245 ions in the 5' end of the U3 sequence of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z.

246 +)-ATPase (SERCA2a) under the control of the Rous sarcoma virus (RSV).

247 polyprotein are intrinsic components of the Rous sarcoma virus assembly pathway.

248 of charged amino acids on the surface of the Rous sarcoma virus capsid protein in the assembly of app

249 ed sequence similarity, the structure of the Rous sarcoma virus capsid protein is similar to the stru

250 In the context of the Rous sarcoma virus Gag polyprotein, only the nucleocapsi

251 purified, slightly truncated version of the Rous sarcoma virus Gag protein, Delta MBD Delta PR, and

252 gion, Mpsi, from the 5' leader region of the Rous sarcoma virus genome that is sufficient to direct t

253 ckaging signal, MPsi, from the 5' end of the Rous sarcoma virus genome.

254 ng MyoD under transcriptional control of the Rous sarcoma virus long terminal repeat.

255 To further study the role of the Rous sarcoma virus MA sequence in the viral replication

256 coli lacZ reporter gene under control of the Rous sarcoma virus promoter and mammalian RNA processing

257 ervative substitutions in this region of the Rous sarcoma virus protein were lethal due to a severe d

258 quenced a small segment of the 3' end of the Rous sarcoma virus, just inside the poly(A) tail, at the

259 o -90 confers FGF2/FSK responsiveness on the Rous sarcoma virus minimal promoter.

260 alovirus (CMV) immediate-early promoter, the Rous sarcoma virus (RSV) long terminal repeat, and the a

261 As also found for other retroviruses, the Rous sarcoma virus structural protein Gag is necessary a

262 We discovered that the Rous sarcoma virus (RSV) Gag protein transiently localiz

263 discovery from Ray Erikson's group that the Rous sarcoma virus (RSV) v-Src-transforming protein had

264 at Y951 facilitates binding of VEGFR2 to the Rous sarcoma (Src) homology 2-domain of T cell-specific

265 Using the Rous sarcoma virus-derived vector RCAS, we previously sh

266 ls from the beta-galactosidase gene when the Rous sarcoma virus promoter is used to drive transgene e

267 proteins that specifically interact with the Rous sarcoma virus (RSV) L domain in vitro and in vivo.

268 dogenous AAV promoters, p5 and p40, with the Rous sarcoma virus (RSV) long terminal repeat (LTR) and

269 ilar to the levels observed in vivo with the Rous sarcoma virus long terminal repeat constitutive pro

270 us, all of the functions associated with the Rous sarcoma virus MA sequence must be contained within

271 Examination of the genomes of three Rous sarcoma virus isolates indicated that codon composi

272 By cryoelectron tomography, Rous sarcoma virus VLPs show an organized hexameric latt

273 pHyde gene under the control of a truncated Rous sarcoma virus (RSV) promoter (AdRSVpHyde) was gener

274 ence appears to be modular, as the unrelated Rous sarcoma virus (RSV) Env can be made Vpu sensitive b

275 Accumulation of unspliced Rous sarcoma virus RNA is facilitated in part by a negat

276 We used Rous sarcoma virus (RSV) Gag together with membrane sens

277 ecades of study on an avian RNA tumor virus, Rous sarcoma virus (RSV).

278 e used cryo-electron tomography to visualize Rous sarcoma virus, the prototypic alpharetrovirus.

279 RNA(Lys3) as the replication primer, whereas Rous sarcoma virus (RSV) uses tRNA(Trp).

280 One mechanism by which Rous sarcoma virus achieves incomplete splicing involves

281 virus (EIAV) is functionally homologous with Rous sarcoma virus (RSV) p2b and human immunodeficiency

282 icken embryo fibroblasts (CEF) infected with Rous sarcoma virus (RSV).

283 contrast, CEF cultures heavily infected with Rous sarcoma virus in the same medium underwent pervasiv